SAB Biotherapeutics (SABS)
NASDAQ:SABS
Want to see SABS full AI Analyst Report?
Top Page
SAB Biotherapeutics
(NASDAQ:SABS)
Select Model
Select Model
Rating:51Neutral
Price Target:
$3.50
▼(-9.09% Downside)
Action:Reiterated
Date:05/14/26
The score is held back primarily by very weak operating performance and heavy cash burn with minimal recent revenue, despite a comparatively low-leverage balance sheet. Technicals are moderately supportive with price above key moving averages and neutral momentum, while valuation remains challenged due to losses and no dividend. Corporate events add modest upside from positive SAB-142 data and operational progress, tempered by dilution and future commitment risks.
Positive Factors
Proprietary Tc bovine platform
SAB's transchromosomic bovine platform is a durable competitive asset: it enables generation of fully human polyclonal antibodies across indications, supports differentiated product profiles versus monoclonals, and creates licensing and partnership revenue potential that can persist independent of any single therapeutic program.
Negative Factors
High cash burn
Consistently large negative operating cash flows create a structural funding requirement: persistent burn of this magnitude increases dependence on capital markets or partners, raises dilution risk, and constrains the company's ability to expand programs or invest in parallel indications over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary Tc bovine platform
SAB's transchromosomic bovine platform is a durable competitive asset: it enables generation of fully human polyclonal antibodies across indications, supports differentiated product profiles versus monoclonals, and creates licensing and partnership revenue potential that can persist independent of any single therapeutic program.
Read all positive factors
SAB Biotherapeutics (SABS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$258.45M
Dividend YieldN/A
Average Volume (3M)398.22K
Price to Earnings (P/E)―
Beta (1Y)0.91
Revenue Growth-100.00%
EPS Growth72.96%
CountryUS
Employees63
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.43
Shares Outstanding76,464,096
10 Day Avg. Volume357,955
30 Day Avg. Volume398,221
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)0.48
Price to Sales (P/S)0.00
P/FCF Ratio-1.58
Enterprise Value/Market Cap0.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.46
Enterprise Value/Ebitda11.48
Forecast
1Y Price Target
$12.57Price Target Upside226.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.93
Revenue Forecast (FY)N/A
SAB Biotherapeutics Business Overview & Revenue Model
Company Description
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine her...
How the Company Makes Money
SAB Biotherapeutics does not have a stable, recurring commercial product revenue base as a clinical-stage company; its earnings are primarily tied to funding and development-related sources. The company can generate revenue through (1) collaborati...
SAB Biotherapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
67
Positive
Cash Flow
21
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 1.32M | 2.24M | 23.90M | 60.88M |
| Gross Profit | -3.10M | -3.08M | -3.47M | -1.51M | 20.61M | 59.22M |
| EBITDA | 1.75M | 16.60M | -28.99M | -38.13M | -15.12M | -15.20M |
| Net Income | -398.43K | 13.27M | -34.11M | -42.19M | -18.74M | -17.14M |
Balance Sheet | ||||||
| Total Assets | 248.47M | 172.81M | 44.20M | 83.94M | 50.90M | 81.14M |
| Cash, Cash Equivalents and Short-Term Investments | 107.39M | 96.59M | 20.76M | 56.57M | 15.05M | 33.21M |
| Total Debt | 6.17M | 5.95M | 4.67M | 5.91M | 5.93M | 8.52M |
| Total Liabilities | 21.22M | 21.32M | 18.23M | 26.64M | 19.85M | 42.59M |
| Stockholders Equity | 227.25M | 151.49M | 25.97M | 57.30M | 31.06M | 38.55M |
Cash Flow | ||||||
| Free Cash Flow | -53.17M | -45.71M | -34.63M | -25.32M | -25.63M | -8.96M |
| Operating Cash Flow | -51.25M | -44.78M | -34.29M | -25.12M | -23.46M | 1.99M |
| Investing Cash Flow | -192.02M | -121.71M | -11.96M | -152.70K | -2.09M | -10.94M |
| Financing Cash Flow | 258.39M | 168.30M | -1.17M | 66.77M | 1.05M | 35.89M |
SAB Biotherapeutics Technical Analysis
Negative
3.85
Price Trends
3.73
Negative
3.88
Negative
3.44
Negative
Market Momentum
-0.09
Positive
41.50
Neutral
14.89
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SABS, the sentiment is Negative. The current price of 3.85 is above the 20-day moving average (MA) of 3.66, above the 50-day MA of 3.73, and above the 200-day MA of 3.44, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 41.50 is Neutral, neither overbought nor oversold. The STOCH value of 14.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SABS.
SAB Biotherapeutics Risk Analysis
SAB Biotherapeutics disclosed 88 risk factors in its most recent earnings report. SAB Biotherapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
SAB Biotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $84.51M | -11.61 | -14.39% | ― | 1.18% | 83.26% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $258.45M | -454.35 | -0.29% | ― | -100.00% | 72.96% | |
46 Neutral | $30.51M | -1.85 | -101.90% | ― | -83.00% | 19.02% | |
46 Neutral | $10.66M | -0.28 | -186.96% | ― | ― | 10.17% | |
43 Neutral | $19.66M | -0.10 | -83.59% | ― | ― | 19.36% |
* Healthcare Sector Average
SABS
SAB Biotherapeutics
3.38
1.52
81.72%
LSTA
Lisata Therapeutics
3.35
0.72
27.18%
NXTC
NextCure
2.95
-3.39
-53.47%
SNSE
Sensei Biotherapeutics
14.65
7.67
109.83%
RLYB
Rallybio
15.95
12.95
432.02%
SAB Biotherapeutics Corporate Events
Business Operations and Strategy
SAB Biotherapeutics Signs Manufacturing Pact for SAB-142
Positive
May 4, 2026
On April 28, 2026, SAB Biotherapeutics entered into a five-year Master Manufacturing Services Agreement with Emergent BioSolutions Canada for clinical and commercial manufacturing of its SAB-142 product at Emergent’s Canadian facility. Emerg...
Business Operations and StrategyProduct-Related Announcements
SAB Biotherapeutics Highlights Positive Phase 1 SAB-142 Results
Positive
Apr 22, 2026
On April 22, 2026, SAB BIO presented new clinical and mechanistic data from its Phase 1 HUMAN trial of SAB-142 in adults with established Stage 3 type 1 diabetes at the Immunology of Diabetes Society Congress in Brisbane. All four patients treated...
Business Operations and StrategyPrivate Placements and Financing
SAB Biotherapeutics Launches Major Equity Financing Offering
Positive
Mar 19, 2026
On March 17, 2026, SAB Biotherapeutics, Inc. entered into an underwriting agreement for an underwritten public offering of 19,324,677 shares of common stock and pre-funded warrants for up to 2,753,246 additional shares, all sold by the company at ...
Business Operations and StrategyProduct-Related Announcements
SAB Biotherapeutics Highlights New Phase 1 SAB-142 Data
Positive
Mar 10, 2026
On March 10, 2026, SAB Biotherapeutics, Inc. reported additional Phase 1 data for its fully human anti-thymocyte globulin candidate SAB-142 in adults with established autoimmune type 1 diabetes. The company simultaneously made a detailed data pres...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.